Ziftomenib Combined with Venetoclax/Azacitidine in Relapsed/Refractory NPM1 -m or KMT2A -r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET-007
Year: 2024
Type: conference-abstract
Source: Blood
Authors: Amir T. Fathi, Ghayas C. Issa, Eunice S. Wang, Harry Erba, Jessica Kaplan Altman, Suresh Kumar Balasubramanian, Gail J. Roboz, Gary J. Schiller, Christine M. McMahon, Neil D. Palmisiano, Mark B Juckett, Yazan F. Madanat, Marcello Rotta, Keith W. Pratz, George Yaghmour, Kalyan Nadiminti, Helen Wei, Marcie Riches, Daniel Corum, Mollie Leoni, Stephen Dale, Amer M. Zeidan
Institutions: Massachusetts General Hospital, The University of Texas MD Anderson Cancer Center, Roswell Park Comprehensive Cancer Center, Duke Cancer Institute, Northwestern University, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Cleveland Clinic, Wayne State University, The Barbara Ann Karmanos Cancer Institute, NewYork–Presbyterian Hospital, Weill Cornell Medicine, University of California, Los Angeles, University of Colorado Anschutz, Rutgers Cancer Institute, University of Minnesota, The University of Texas Southwestern Medical Center, Colorado Blood Cancer Institute, University of Pennsylvania, University of Southern California, USC Norris Comprehensive Cancer Center, University of Wisconsin–Madison, University of Wisconsin Carbone Cancer Center, Kura Oncology (United States), Yale University
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4405039164